Revenue: As of FY2025 Q3, the actual value is USD 552 K.

EPS: As of FY2025 Q3, the actual value is USD -0.17.

EBIT: As of FY2025 Q3, the actual value is USD -42.35 M.

Segment Revenue

• Total revenue for the third quarter of 2025 was $552,000, with product revenue at $505,000 and service revenue at $47,000.

Operational Metrics

• Gross profit for the third quarter was $194,000, resulting in a gross margin of 35%.
• Total operating expenses were $40.0 million, compared to $28.5 million in the same period of the prior year.
• Adjusted total operating expenses were $21.4 million, down from $26.0 million in the prior year.
• Net loss for the third quarter was $35.7 million, compared to a net loss of $25.3 million in the same period of the prior year.
• Adjusted EBITDA was negative $20.1 million, compared to negative $24.5 million in the prior year.

Cash Flow

• As of September 30, 2025, the company had cash and cash equivalents and investments in marketable securities totaling $230.5 million, expected to support operations into the second quarter of 2028.

Unique Metrics

• The company highlighted successful sequencing runs on a prototype Proteus system and the launch of the version 4 Sequencing Kit.

Outlook / Guidance

• Quantum-Si remains on track to launch the version 3 Library Prep Kit before the end of 2025 and aims to deliver the Proteus platform in the second half of 2026.
• The company plans to continue using a mix of instrument acquisition options to increase awareness and build momentum towards the future Proteus platform launch.